Pharmafile Logo

VBH

- PMLiVE

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change

Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly.

Say Communications

Transforming Healthcare Through the Power of Patients

Esther Schorr, Co-founder and Chief Operating Officer of Patient Power LLC, discusses non-linear journey to patient education and Patient Power's mission to empower patients and their loved ones to take...

Impetus Digital

- PMLiVE

Novartis to pay up to $1.5bn for Gyroscope

The acquisition of ocular gene therapy company, Gyroscope, adds GT005 to the Novartis portfolio – a one-time gene therapy for geographic atrophy, a leading cause of blindness

- PMLiVE

Novartis strengthens links with BeiGene in a deal that could be worth up to $1bn

Novartis is to pay $300m upfront to BeiGene in a multifaceted deal to enhance its oncology portfolio and expand coverage of the Chinese market

- PMLiVE

Can tobacco companies really reinvent themselves as healthcare companies?

A surprising move by key player, Phillip Morris, has called attention to the start of a new era for the tobacco industry. But can tobacco companies reinvent themselves as healthcare...

Say Communications

- PMLiVE

Novartis pulls out of Mesoblast deal

Shares in Mesoblast dropped sharply after Novartis pulled out of a deal announced earlier this year to collaborate on COVID-19 medicine remestemcel-L, citing poor trial data

- PMLiVE

Onyx Health Announces Two Top Appointments

Onyx health have made two senior appointments to their communications team

Onyx Health

Accelerating Revenue Cycle Performance in the Healthcare Industry

Michael Duke, Principal Healthcare Consultant at Baker Tilly US, discusses the importance of data and analytics for internal audits, organizational risk reduction, workflow automation, and to drive value in healthcare....

Impetus Digital

- PMLiVE

Roche and Novartis part ways with share purchase

Novartis is to sell its one-third stake in Roche for more than $20bn, paving the way for potential acquisitions

- PMLiVE

Novartis invests $1.3bn in protein degradation technology

Novartis will work with UK-based start-up Dunad Therapeutics to develop protein degradation drugs

- PMLiVE

Novartis receives approval for third-generation leukaemia therapy

With a novel mechanism of action, Scemblix is a new option for people with chronic myeloid leukaemia who experience intolerance or inadequate response to standard therapy

- PMLiVE

Novartis sales top £13bn in Q3 as the company reviews its generic business Sandoz

The company has started a strategic review of Sandoz as sales drop 20% in ‘challenging’ US market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links